Metastatic Triple Negative Breast Cancer (UNC Phase II Trial, J Immunother Cancer 2022) - iAtlas Harmonized

Summary

Metastatic Triple Negative Breast Cancer (UNC Phase II Trial, J Immunother Cancer 2022) - iAtlas Harmonized is a study catalogued by cBioPortal DataHub under the cancer-type code brca. EvidenceHelix groups it with breast studies.

Study description

Whole-exome sequencing and neoantigen landscape analysis of 31 patients with pretreated metastatic triple-negative breast cancer (mTNBC) enrolled in a phase II trial (https://clinicaltrials.gov/study/NCT02768701) evaluating whether a single low dose of cyclophosphamide administered prior to the PD-1 inhibitor pembrolizumab could improve progression-free survival compared with historical controls. The reprocessing of raw sequencing data is coordinated by CRI iAtlas (https://cri-iatlas.org/).

Text as published in the source's study metadata.

Citation & PubMed

Anders et al. J Immunother Cancer 2022

Linked PubMed records: PMID 35121644

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

brca_iatlas_anders_2022

Short name

not given

Source cancer-type code

brca

Reference genome

hg38

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Anders et al. J Immunother Cancer 2022

• PubMed record 35121644 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Breast Cancer (HTAN, 2022)

  An omic and multidimensional spatial (OMS) atlas generated from four serial biopsies of an individual with metastatic breast cancer during 3.5 years of therapy. This resource links detailed, longitudinal clinical meta…

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)

  Targeted sequencing of 2509 primary breast tumors with 548 matched normals.

  BreastOther published and consortium studiesSource code brcaPubMed 3

• Breast Cancer (SMC 2018)

  Whole-exome sequencing of 187 primary tumors from a Korean breast cancer cohort (SMC).

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Breast Cancer Xenografts (British Columbia, Nature 2015)

  Whole genome/targeted sequencing to evaluate the clonal dynamics in 116 breast cancer patient xenografts.

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Breast Invasive Carcinoma (British Columbia, Nature 2012)

  Whole genome/exome sequencing analysis of 65 breast cancer samples

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Breast Invasive Carcinoma (Broad, Nature 2012)

  Whole-exome sequencing of 103 breast cancer tumor/normal sample pairs. Generated by the Broad Institute.

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Breast Invasive Carcinoma (Sanger, Nature 2012)

  Whole exome sequencing from 100 breast cancer tumor/normal sample pairs. Generated by the Sanger Institute.

  BreastOther published and consortium studiesSource code brcaPubMed 1

• Metastatic Breast Cancer (AURORA US Network, Nat Cancer 2023)

  Whole exome and low-pass whole genome sequencing of 55 patients with metastatic breast cancer (53 primary cancers and 102 metastases) and their matched normals. Retrospective Tissue Collection; an initiative of the Br…

  BreastOther published and consortium studiesSource code brcaPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.